ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Drug for Blood Cancers Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-32M17201
Home | Market Reports | Health| Health Conditions| Cancer
Global Targeted Drug for Blood Cancers Market Research Report 2024
BUY CHAPTERS

Global Targeted Drug for Blood Cancers Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-32M17201
Report
November 2025
Pages:174
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis Pharms
Bristol–Myers Squibb
IL-Yang Pharms
Pfizer Inc
Takeda Oncology
Johnson & Johnson
Gilead Sciences
AbbVie
Genentech Inc
Sanofi
Amgen Inc
Roche
GlaxoSmithKline PLC
Astrazeneca plc
BeiGene Ltd
Eli Lilly
Merck
Johnson & Johnson

Targeted Drug for Blood Cancers Market

The global Targeted Drug for Blood Cancers market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Blood cancers (Leukemia) is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.
Targeted drugs for blood cancers are a class of pharmaceuticals designed to specifically target and attack cancer cells while minimizing harm to healthy cells. These drugs work by interfering with specific molecules or pathways that are crucial for cancer cell growth and survival. Examples of targeted drugs for blood cancers include monoclonal antibodies, small molecule inhibitors, and immunotherapies, which may target proteins on the surface of cancer cells, enzymes involved in cell signaling pathways, or immune checkpoints. By selectively targeting cancer cells, these drugs offer the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. Targeted drugs have revolutionized the treatment landscape for blood cancers, offering new options for patients and improving outcomes.
As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.
Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.
Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.
The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Drug for Blood Cancers market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Targeted Drug for Blood Cancers Market Report

Report Metric Details
Report Name Targeted Drug for Blood Cancers Market
Segment by Type
  • Monoclonal Antibodies
  • Small-Molecule Drugs
Segment by Application
  • Acute Myeloid Leukemia (AML)
  • Chronic Myeloid Leukemia (CML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis Pharms, Bristol-Myers Squibb, IL-Yang Pharms, Pfizer, Takeda Oncology, Johnson & Johnson, Gilead Sciences, Abbvie, Genentech, Sanofi, Amgen, Roche, GlaxoSmithKline, AstraZeneca, BeiGene, Eli Lilly, Merck
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Targeted Drug for Blood Cancers study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Targeted Drug for Blood Cancers Market report?

Ans: The main players in the Targeted Drug for Blood Cancers Market are Novartis Pharms, Bristol-Myers Squibb, IL-Yang Pharms, Pfizer, Takeda Oncology, Johnson & Johnson, Gilead Sciences, Abbvie, Genentech, Sanofi, Amgen, Roche, GlaxoSmithKline, AstraZeneca, BeiGene, Eli Lilly, Merck

What are the Application segmentation covered in the Targeted Drug for Blood Cancers Market report?

Ans: The Applications covered in the Targeted Drug for Blood Cancers Market report are Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)

What are the Type segmentation covered in the Targeted Drug for Blood Cancers Market report?

Ans: The Types covered in the Targeted Drug for Blood Cancers Market report are Monoclonal Antibodies, Small-Molecule Drugs

1 Study Coverage
1.1 Introduction to Targeted Drug for Blood Cancers: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Drug for Blood Cancers Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibodies
1.2.3 Small-Molecule Drugs
1.3 Market Segmentation by Application
1.3.1 Global Targeted Drug for Blood Cancers Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Acute Myeloid Leukemia (AML)
1.3.3 Chronic Myeloid Leukemia (CML)
1.3.4 Acute Lymphoblastic Leukemia (ALL)
1.3.5 Chronic Lymphocytic Leukemia (CLL)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Drug for Blood Cancers Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Drug for Blood Cancers Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Targeted Drug for Blood Cancers Sales Estimates and Forecasts 2020-2031
2.4 Global Targeted Drug for Blood Cancers Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Targeted Drug for Blood Cancers Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Targeted Drug for Blood Cancers Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Monoclonal Antibodies Market Size by Manufacturers
3.5.2 Small-Molecule Drugs Market Size by Manufacturers
3.6 Global Targeted Drug for Blood Cancers Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Drug for Blood Cancers Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Targeted Drug for Blood Cancers Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Drug for Blood Cancers Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Targeted Drug for Blood Cancers Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Targeted Drug for Blood Cancers Sales and Revenue by Type (2020-2031)
6.4 North America Targeted Drug for Blood Cancers Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Drug for Blood Cancers Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Targeted Drug for Blood Cancers Sales and Revenue by Type (2020-2031)
7.4 Europe Targeted Drug for Blood Cancers Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Drug for Blood Cancers Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Targeted Drug for Blood Cancers Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Targeted Drug for Blood Cancers Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Targeted Drug for Blood Cancers Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Targeted Drug for Blood Cancers Sales and Revenue by Type (2020-2031)
9.4 Central and South America Targeted Drug for Blood Cancers Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Drug for Blood Cancers Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Targeted Drug for Blood Cancers Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Targeted Drug for Blood Cancers Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Drug for Blood Cancers Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis Pharms
11.1.1 Novartis Pharms Corporation Information
11.1.2 Novartis Pharms Business Overview
11.1.3 Novartis Pharms Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.1.4 Novartis Pharms Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Pharms Targeted Drug for Blood Cancers Sales by Product in 2024
11.1.6 Novartis Pharms Targeted Drug for Blood Cancers Sales by Application in 2024
11.1.7 Novartis Pharms Targeted Drug for Blood Cancers Sales by Geographic Area in 2024
11.1.8 Novartis Pharms Targeted Drug for Blood Cancers SWOT Analysis
11.1.9 Novartis Pharms Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Corporation Information
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.2.4 Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales by Product in 2024
11.2.6 Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales by Application in 2024
11.2.7 Bristol-Myers Squibb Targeted Drug for Blood Cancers Sales by Geographic Area in 2024
11.2.8 Bristol-Myers Squibb Targeted Drug for Blood Cancers SWOT Analysis
11.2.9 Bristol-Myers Squibb Recent Developments
11.3 IL-Yang Pharms
11.3.1 IL-Yang Pharms Corporation Information
11.3.2 IL-Yang Pharms Business Overview
11.3.3 IL-Yang Pharms Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.3.4 IL-Yang Pharms Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 IL-Yang Pharms Targeted Drug for Blood Cancers Sales by Product in 2024
11.3.6 IL-Yang Pharms Targeted Drug for Blood Cancers Sales by Application in 2024
11.3.7 IL-Yang Pharms Targeted Drug for Blood Cancers Sales by Geographic Area in 2024
11.3.8 IL-Yang Pharms Targeted Drug for Blood Cancers SWOT Analysis
11.3.9 IL-Yang Pharms Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.4.4 Pfizer Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer Targeted Drug for Blood Cancers Sales by Product in 2024
11.4.6 Pfizer Targeted Drug for Blood Cancers Sales by Application in 2024
11.4.7 Pfizer Targeted Drug for Blood Cancers Sales by Geographic Area in 2024
11.4.8 Pfizer Targeted Drug for Blood Cancers SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 Takeda Oncology
11.5.1 Takeda Oncology Corporation Information
11.5.2 Takeda Oncology Business Overview
11.5.3 Takeda Oncology Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.5.4 Takeda Oncology Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Takeda Oncology Targeted Drug for Blood Cancers Sales by Product in 2024
11.5.6 Takeda Oncology Targeted Drug for Blood Cancers Sales by Application in 2024
11.5.7 Takeda Oncology Targeted Drug for Blood Cancers Sales by Geographic Area in 2024
11.5.8 Takeda Oncology Targeted Drug for Blood Cancers SWOT Analysis
11.5.9 Takeda Oncology Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.6.4 Johnson & Johnson Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Johnson & Johnson Recent Developments
11.7 Gilead Sciences
11.7.1 Gilead Sciences Corporation Information
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.7.4 Gilead Sciences Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Gilead Sciences Recent Developments
11.8 Abbvie
11.8.1 Abbvie Corporation Information
11.8.2 Abbvie Business Overview
11.8.3 Abbvie Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.8.4 Abbvie Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Abbvie Recent Developments
11.9 Genentech
11.9.1 Genentech Corporation Information
11.9.2 Genentech Business Overview
11.9.3 Genentech Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.9.4 Genentech Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Genentech Recent Developments
11.10 Sanofi
11.10.1 Sanofi Corporation Information
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.10.4 Sanofi Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Sanofi Recent Developments
11.11 Amgen
11.11.1 Amgen Corporation Information
11.11.2 Amgen Business Overview
11.11.3 Amgen Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.11.4 Amgen Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Amgen Recent Developments
11.12 Roche
11.12.1 Roche Corporation Information
11.12.2 Roche Business Overview
11.12.3 Roche Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.12.4 Roche Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Roche Recent Developments
11.13 GlaxoSmithKline
11.13.1 GlaxoSmithKline Corporation Information
11.13.2 GlaxoSmithKline Business Overview
11.13.3 GlaxoSmithKline Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.13.4 GlaxoSmithKline Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 GlaxoSmithKline Recent Developments
11.14 AstraZeneca
11.14.1 AstraZeneca Corporation Information
11.14.2 AstraZeneca Business Overview
11.14.3 AstraZeneca Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.14.4 AstraZeneca Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 AstraZeneca Recent Developments
11.15 BeiGene
11.15.1 BeiGene Corporation Information
11.15.2 BeiGene Business Overview
11.15.3 BeiGene Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.15.4 BeiGene Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 BeiGene Recent Developments
11.16 Eli Lilly
11.16.1 Eli Lilly Corporation Information
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.16.4 Eli Lilly Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Eli Lilly Recent Developments
11.17 Merck
11.17.1 Merck Corporation Information
11.17.2 Merck Business Overview
11.17.3 Merck Targeted Drug for Blood Cancers Product Models, Descriptions and Specifications
11.17.4 Merck Targeted Drug for Blood Cancers Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Merck Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Targeted Drug for Blood Cancers Industry Chain
12.2 Targeted Drug for Blood Cancers Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Targeted Drug for Blood Cancers Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Targeted Drug for Blood Cancers Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Drug for Blood Cancers Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Drug for Blood Cancers Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Novartis Pharms
Bristol–Myers Squibb
IL-Yang Pharms
Pfizer Inc
Takeda Oncology
Johnson & Johnson
Gilead Sciences
AbbVie
Genentech Inc
Sanofi
Amgen Inc
Roche
GlaxoSmithKline PLC
Astrazeneca plc
BeiGene Ltd
Eli Lilly
Merck
Johnson & Johnson
List of Tables
 Table 1. Global Targeted Drug for Blood Cancers Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Targeted Drug for Blood Cancers Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Targeted Drug for Blood Cancers Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Targeted Drug for Blood Cancers Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Targeted Drug for Blood Cancers Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Units)
 Table 7. Global Targeted Drug for Blood Cancers Sales by Region (2020-2025) & (Units)
 Table 8. Global Targeted Drug for Blood Cancers Sales by Region (2026-2031) & (Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Targeted Drug for Blood Cancers Sales by Manufacturers (2020-2025) & (Units)
 Table 11. Global Targeted Drug for Blood Cancers Sales Share by Manufacturers (2020-2025)
 Table 12. Global Targeted Drug for Blood Cancers Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Targeted Drug for Blood Cancers Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Targeted Drug for Blood Cancers by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug for Blood Cancers as of 2024)
 Table 16. Global Targeted Drug for Blood Cancers Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Targeted Drug for Blood Cancers Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Targeted Drug for Blood Cancers Manufacturing Base and Headquarters
 Table 19. Global Targeted Drug for Blood Cancers Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Targeted Drug for Blood Cancers Sales by Type (2020-2025) & (Units)
 Table 23. Global Targeted Drug for Blood Cancers Sales by Type (2026-2031) & (Units)
 Table 24. Global Targeted Drug for Blood Cancers Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Targeted Drug for Blood Cancers Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Targeted Drug for Blood Cancers ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Targeted Drug for Blood Cancers Sales by Application (2020-2025) & (Units)
 Table 29. Global Targeted Drug for Blood Cancers Sales by Application (2026-2031) & (Units)
 Table 30. Targeted Drug for Blood Cancers High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Targeted Drug for Blood Cancers Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Targeted Drug for Blood Cancers Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Targeted Drug for Blood Cancers ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Targeted Drug for Blood Cancers Growth Accelerators and Market Barriers
 Table 37. North America Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Targeted Drug for Blood Cancers Sales (Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Targeted Drug for Blood Cancers Growth Accelerators and Market Barriers
 Table 40. Europe Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Targeted Drug for Blood Cancers Sales (Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Targeted Drug for Blood Cancers Sales (Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Targeted Drug for Blood Cancers Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Targeted Drug for Blood Cancers Investment Opportunities and Key Challenges
 Table 47. Central and South America Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Targeted Drug for Blood Cancers Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Targeted Drug for Blood Cancers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Novartis Pharms Corporation Information
 Table 51. Novartis Pharms Description and Major Businesses
 Table 52. Novartis Pharms Product Models, Descriptions and Specifications
 Table 53. Novartis Pharms Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Novartis Pharms Sales Value Proportion by Product in 2024
 Table 55. Novartis Pharms Sales Value Proportion by Application in 2024
 Table 56. Novartis Pharms Sales Value Proportion by Geographic Area in 2024
 Table 57. Novartis Pharms Targeted Drug for Blood Cancers SWOT Analysis
 Table 58. Novartis Pharms Recent Developments
 Table 59. Bristol-Myers Squibb Corporation Information
 Table 60. Bristol-Myers Squibb Description and Major Businesses
 Table 61. Bristol-Myers Squibb Product Models, Descriptions and Specifications
 Table 62. Bristol-Myers Squibb Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Bristol-Myers Squibb Sales Value Proportion by Product in 2024
 Table 64. Bristol-Myers Squibb Sales Value Proportion by Application in 2024
 Table 65. Bristol-Myers Squibb Sales Value Proportion by Geographic Area in 2024
 Table 66. Bristol-Myers Squibb Targeted Drug for Blood Cancers SWOT Analysis
 Table 67. Bristol-Myers Squibb Recent Developments
 Table 68. IL-Yang Pharms Corporation Information
 Table 69. IL-Yang Pharms Description and Major Businesses
 Table 70. IL-Yang Pharms Product Models, Descriptions and Specifications
 Table 71. IL-Yang Pharms Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. IL-Yang Pharms Sales Value Proportion by Product in 2024
 Table 73. IL-Yang Pharms Sales Value Proportion by Application in 2024
 Table 74. IL-Yang Pharms Sales Value Proportion by Geographic Area in 2024
 Table 75. IL-Yang Pharms Targeted Drug for Blood Cancers SWOT Analysis
 Table 76. IL-Yang Pharms Recent Developments
 Table 77. Pfizer Corporation Information
 Table 78. Pfizer Description and Major Businesses
 Table 79. Pfizer Product Models, Descriptions and Specifications
 Table 80. Pfizer Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Pfizer Sales Value Proportion by Product in 2024
 Table 82. Pfizer Sales Value Proportion by Application in 2024
 Table 83. Pfizer Sales Value Proportion by Geographic Area in 2024
 Table 84. Pfizer Targeted Drug for Blood Cancers SWOT Analysis
 Table 85. Pfizer Recent Developments
 Table 86. Takeda Oncology Corporation Information
 Table 87. Takeda Oncology Description and Major Businesses
 Table 88. Takeda Oncology Product Models, Descriptions and Specifications
 Table 89. Takeda Oncology Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Takeda Oncology Sales Value Proportion by Product in 2024
 Table 91. Takeda Oncology Sales Value Proportion by Application in 2024
 Table 92. Takeda Oncology Sales Value Proportion by Geographic Area in 2024
 Table 93. Takeda Oncology Targeted Drug for Blood Cancers SWOT Analysis
 Table 94. Takeda Oncology Recent Developments
 Table 95. Johnson & Johnson Corporation Information
 Table 96. Johnson & Johnson Description and Major Businesses
 Table 97. Johnson & Johnson Product Models, Descriptions and Specifications
 Table 98. Johnson & Johnson Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Johnson & Johnson Recent Developments
 Table 100. Gilead Sciences Corporation Information
 Table 101. Gilead Sciences Description and Major Businesses
 Table 102. Gilead Sciences Product Models, Descriptions and Specifications
 Table 103. Gilead Sciences Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Gilead Sciences Recent Developments
 Table 105. Abbvie Corporation Information
 Table 106. Abbvie Description and Major Businesses
 Table 107. Abbvie Product Models, Descriptions and Specifications
 Table 108. Abbvie Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Abbvie Recent Developments
 Table 110. Genentech Corporation Information
 Table 111. Genentech Description and Major Businesses
 Table 112. Genentech Product Models, Descriptions and Specifications
 Table 113. Genentech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Genentech Recent Developments
 Table 115. Sanofi Corporation Information
 Table 116. Sanofi Description and Major Businesses
 Table 117. Sanofi Product Models, Descriptions and Specifications
 Table 118. Sanofi Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Sanofi Recent Developments
 Table 120. Amgen Corporation Information
 Table 121. Amgen Description and Major Businesses
 Table 122. Amgen Product Models, Descriptions and Specifications
 Table 123. Amgen Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Amgen Recent Developments
 Table 125. Roche Corporation Information
 Table 126. Roche Description and Major Businesses
 Table 127. Roche Product Models, Descriptions and Specifications
 Table 128. Roche Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 129. Roche Recent Developments
 Table 130. GlaxoSmithKline Corporation Information
 Table 131. GlaxoSmithKline Description and Major Businesses
 Table 132. GlaxoSmithKline Product Models, Descriptions and Specifications
 Table 133. GlaxoSmithKline Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 134. GlaxoSmithKline Recent Developments
 Table 135. AstraZeneca Corporation Information
 Table 136. AstraZeneca Description and Major Businesses
 Table 137. AstraZeneca Product Models, Descriptions and Specifications
 Table 138. AstraZeneca Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 139. AstraZeneca Recent Developments
 Table 140. BeiGene Corporation Information
 Table 141. BeiGene Description and Major Businesses
 Table 142. BeiGene Product Models, Descriptions and Specifications
 Table 143. BeiGene Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 144. BeiGene Recent Developments
 Table 145. Eli Lilly Corporation Information
 Table 146. Eli Lilly Description and Major Businesses
 Table 147. Eli Lilly Product Models, Descriptions and Specifications
 Table 148. Eli Lilly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 149. Eli Lilly Recent Developments
 Table 150. Merck Corporation Information
 Table 151. Merck Description and Major Businesses
 Table 152. Merck Product Models, Descriptions and Specifications
 Table 153. Merck Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 154. Merck Recent Developments
 Table 155. Key Raw Materials Distribution
 Table 156. Raw Materials Key Suppliers
 Table 157. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 158. Milestones in Production Technology Evolution
 Table 159. Distributors List
 Table 160. Market Trends and Market Evolution
 Table 161. Market Drivers and Opportunities
 Table 162. Market Challenges, Risks, and Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources


List of Figures
 Figure 1. Targeted Drug for Blood Cancers Product Picture
 Figure 2. Global Targeted Drug for Blood Cancers Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Monoclonal Antibodies Product Picture
 Figure 4. Small-Molecule Drugs Product Picture
 Figure 5. Global Targeted Drug for Blood Cancers Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Acute Myeloid Leukemia (AML)
 Figure 7. Chronic Myeloid Leukemia (CML)
 Figure 8. Acute Lymphoblastic Leukemia (ALL)
 Figure 9. Chronic Lymphocytic Leukemia (CLL)
 Figure 10. Targeted Drug for Blood Cancers Report Years Considered
 Figure 11. Global Targeted Drug for Blood Cancers Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Targeted Drug for Blood Cancers Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Targeted Drug for Blood Cancers Revenue Market Share by Region (2020-2031)
 Figure 15. Global Targeted Drug for Blood Cancers Sales (2020-2031) & (Units)
 Figure 16. Global Targeted Drug for Blood Cancers Sales (CAGR) by Region (2020-2031) (Units)
 Figure 17. Global Targeted Drug for Blood Cancers Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers Targeted Drug for Blood Cancers Sales Volume Market Share in 2024
 Figure 19. Global Targeted Drug for Blood Cancers Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Monoclonal Antibodies Revenue Market Share by Manufacturer in 2024
 Figure 22. Small-Molecule Drugs Revenue Market Share by Manufacturer in 2024
 Figure 23. Global Targeted Drug for Blood Cancers Sales Market Share by Type (2020-2031)
 Figure 24. Global Targeted Drug for Blood Cancers Revenue Market Share by Type (2020-2031)
 Figure 25. Global Targeted Drug for Blood Cancers Sales Market Share by Application (2020-2031)
 Figure 26. Global Targeted Drug for Blood Cancers Revenue Market Share by Application (2020-2031)
 Figure 27. North America Targeted Drug for Blood Cancers Sales YoY (2020-2031) & (Units)
 Figure 28. North America Targeted Drug for Blood Cancers Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Manufacturers Targeted Drug for Blood Cancers Sales Revenue (US$ Million) in 2024
 Figure 30. North America Targeted Drug for Blood Cancers Sales Volume (Units) by Type (2020- 2031)
 Figure 31. North America Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America Targeted Drug for Blood Cancers Sales Volume (Units) by Application (2020-2031)
 Figure 33. North America Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 34. US Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 35. Canada Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 36. Mexico Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 37. Europe Targeted Drug for Blood Cancers Sales YoY (2020-2031) & (Units)
 Figure 38. Europe Targeted Drug for Blood Cancers Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Manufacturers Targeted Drug for Blood Cancers Sales Revenue (US$ Million) in 2024
 Figure 40. Europe Targeted Drug for Blood Cancers Sales Volume (Units) by Type (2020-2031)
 Figure 41. Europe Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe Targeted Drug for Blood Cancers Sales Volume (Units) by Application (2020-2031)
 Figure 43. Europe Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Germany Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 45. France Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 46. U.K. Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 47. Italy Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 48. Russia Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Targeted Drug for Blood Cancers Sales YoY (2020-2031) & (Units)
 Figure 50. Asia-Pacific Targeted Drug for Blood Cancers Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Top 8 Manufacturers Targeted Drug for Blood Cancers Sales Revenue (US$ Million) in 2024
 Figure 52. Asia-Pacific Targeted Drug for Blood Cancers Sales Volume (Units) by Type (2020- 2031)
 Figure 53. Asia-Pacific Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 54. Asia-Pacific Targeted Drug for Blood Cancers Sales Volume (Units) by Application (2020-2031)
 Figure 55. Asia-Pacific Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Indonesia Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 57. Japan Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 58. South Korea Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 59. China Taiwan Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 60. India Targeted Drug for Blood Cancers Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America Targeted Drug for Blood Cancers Sales YoY (2020-2031) & (Units)
 Figure 62. Central and South America Targeted Drug for Blood Cancers Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Manufacturers Targeted Drug for Blood Cancers Sales Revenue (US$ Million) in 2024
 Figure 64. Central and South America Targeted Drug for Blood Cancers Sales Volume (Units) by Type (2021-2031)
 Figure 65. Central and South America Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Central and South America Targeted Drug for Blood Cancers Sales Volume (Units) by Application (2020-2031)
 Figure 67. Central and South America Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 68. Brazil Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 69. Argentina Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 70. Middle East, and Africa Targeted Drug for Blood Cancers Sales YoY (2020-2031) & (Units)
 Figure 71. Middle East and Africa Targeted Drug for Blood Cancers Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Middle East and Africa Top 5 Manufacturers Targeted Drug for Blood Cancers Sales Revenue (US$ Million) in 2024
 Figure 73. Middle East and Africa Targeted Drug for Blood Cancers Sales Volume (Units) by Type (2021-2031)
 Figure 74. South America Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Middle East and Africa Targeted Drug for Blood Cancers Sales Volume (Units) by Application (2020-2031)
 Figure 76. Middle East and Africa Targeted Drug for Blood Cancers Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. GCC Countries Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 78. Turkey Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 79. Egypt Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 80. South Africa Targeted Drug for Blood Cancers Revenue (2020-2025) & (US$ Million)
 Figure 81. Targeted Drug for Blood Cancers Industry Chain Mapping
 Figure 82. Regional Targeted Drug for Blood Cancers Manufacturing Base Distribution (%)
 Figure 83. Global Targeted Drug for Blood Cancers Production Market Share by Region (2020-2031)
 Figure 84. Targeted Drug for Blood Cancers Production Process
 Figure 85. Regional Targeted Drug for Blood Cancers Production Cost Structure
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Targeted Drug for Leukemia Market Research Report 2024
Global Targeted Therapy Drugs for Leukemia Market Research Report 2024
Global Leukemia Targeted Therapy Drugs Market Research Report 2024
Global Blood Tumor Drugs Market Research Report 2024
Global Hematologic Malignancies Treatment Market Research Report 2024
Acute Lymphocytic Lymphoblastic Leukemia Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematologic Oncology Treatment Market Research Report 2024
Global Chronic Myeloid Leukemia Treatment Drugs Market Research Report 2025
Global Blood Tumor Treatment Market Research Report 2024
Acute Lymphocytic Lymphoblastic Leukemia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Lymphoblastic Leukemia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Blood Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Lymphocytic Lymphoblastic Leukemia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Lymphocytic Leukemia Drugs Market Research Report 2024
Acute Lymphocytic Leukemia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Lymphoblastic Leukemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Lymphoblastic Leukemia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Myeloid Leukemia CML Treatment Market Insights Forecast to 2030
Global Acute Lymphocytic Lymphoblastic Leukemia ALL Therapeutics Market Insights Forecast to 2030

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions